Nucs AI Launches TrackPSMA to Revolutionize Prostate Cancer Treatment

Nucs AI has introduced TrackPSMA, an innovative tool designed to enhance the evaluation of treatment responses in prostate cancer patients. Launched on November 25, 2025, this AI-driven platform aims to address the significant challenge faced by over half of prostate cancer patients undergoing radioligand therapy who may not respond to treatment.

Radioligand therapy is gaining recognition as a promising cancer treatment, yet it is confronted with critical issues: determining which patients will derive the most benefit and establishing standardized methods for assessing treatment efficacy. Research indicates that approximately 54% of individuals receiving this therapy may not experience any benefits, highlighting the urgent need for early identification of non-responders to facilitate timely adjustments to treatment plans.

TrackPSMA employs artificial intelligence to analyze PSMA-PET/CT scans over time, allowing physicians to monitor patients’ responses to treatment effectively. This tool provides quantitative insights that assist healthcare providers in making informed decisions regarding dosage adjustments or switching to more effective therapies.

Transforming Treatment Assessments

The platform offers a comparative assessment that quantifies changes in disease progression through screening and follow-up scans. This advancement improves a traditionally unstructured and manual evaluation process, enhancing the objectivity and reliability of assessments. Moreover, TrackPSMA facilitates lesion-by-lesion tracking, which enables clinicians to observe changes in individual lesions over time.

According to Farid Yagubbayli, Chief Technology Officer of Nucs AI, “Being able to track disease progression lesion by lesion represents a fundamental shift in how experts understand and manage cancer over time.” He emphasized that the ability to measure therapy response objectively across varying conditions transforms a previously subjective process into a standardized, data-driven approach.

Nijat Ahmadov, Chief Executive Officer of Nucs AI, added, “TrackPSMA also represents a critical step forward in applying AI to radioligand therapy treatment planning.” He noted that the tool’s automated and precise assessments enhance understanding of patient-specific and tumor-specific scenarios, aiding physicians and drug manufacturers in identifying effective treatments.

Enhancing Clinical Efficiency

With the introduction of TrackPSMA, physicians can now assess whether patients benefit from radiopharmaceutical treatments more efficiently. This tool, in conjunction with Nucs AI’s existing solutions—DeepPSMA and SelectPSMA—has already demonstrated a significant reduction in manual analysis and improved patient stratification for radioligand therapy.

By streamlining workflows and minimizing errors, Nucs AI not only alleviates the administrative burden on radiologists but also enhances diagnostic accuracy, reduces clinician burnout, and ultimately lowers healthcare costs.

The launch of TrackPSMA is a significant milestone in Nucs AI’s mission to redefine the role of artificial intelligence in medical imaging. Collaborating with renowned institutions like Johns Hopkins, the company is advancing its portfolio to meet the growing global demand for AI-powered radiology solutions.

For those interested in learning more about Nucs AI’s innovations, the company invites attendees to visit their booth at RSNA 2025, where they will showcase how they are transforming evidence-based response evaluation for next-generation radiopharmaceutical therapies.

Nucs AI is dedicated to revolutionizing precision radiology through its suite of AI-powered imaging solutions. These advancements empower clinicians to make faster, more informed decisions, setting new standards for AI-assisted diagnostics in the realm of cancer treatment. For additional information regarding partnership opportunities, visit www.nucs.ai or contact them via email.